跳至主要内容
临床试验/NCT02955719
NCT02955719已完成不适用

CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In Dementia: Depression, Anxiety, and Mild Cognitive Impairment

Centre for Addiction and Mental Health1 个研究点 分布在 1 个国家目标入组 145 人开始时间: 2016年3月30日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
145
试验地点
1
主要终点
Change in anxiety/depression/quality of life (QOL) scores among participants in the ICP and comparison groups

研究概览

简要总结

Age remains the single most significant risk factor for developing dementia, particularly Alzheimer's dementia (AD). Given the rate at which Canada's population is aging, the quest to determine modifiable risk factors, whether by prevention, earlier detection, or an ability to slow the rate of decline, is a key priority in health care. Primary care is likely to play a pivotal role in this initiative. Collaborative mental health care between primary care providers and mental health clinicians has been demonstrated to be effective at the patient and system levels. Thus, the overall goal of this project is to assess impact and feasibility of implementing a collaborative care evidence-based Integrated Care Pathway (ICP) in addressing three potentially reversible risk factors at high risk for developing AD: anxiety, depression, or mild cognitive impairment (MCI).

详细描述

The investigators will enroll 150 participants overall (CAMH and McMaster). Seventy-five will be cases who will be enrolled into the ICP arm of the study and these will be patients born in the calendar year 1951, 1953 or 1955. The investigators will enroll an additional 75 controls that were born in the calendar year 1950, 1952 or 1956.

Patients of general practitioners being seen at primary healthcare clinics in the Greater Toronto Area and in Hamilton, who were born in the calendar year 1950, 1951, 1952, 1953, 1955, or 1956 will be consented and screened for anxiety, depression, and Mild Cognitive Impairment (MCI).

If patients born in 1951, 1953 and 1955 reach a threshold level of anxiety, depression, or MCI symptom burden and have a confirmed diagnosis, rather than receive treatment as usual, the participants will be enrolled into an Integrated Care Pathway (ICP), which offers evidence-informed treatment for the management of these syndromes in a routine, algorithmic fashion. All enrolled cases entered in the study will be provided with general interventions that address lifestyle and medical factors that both contribute to these syndromes and are thought to predispose patients to develop dementia. If the symptom burden is severe enough, based on standardized assessments, evidence-based psychopharmacology (a trial of sertraline and/or venlafaxine) will also be offered, with a standardized titration schedule. Collaboration will be built into the ICP - a psychiatrist will be present at the clinic and in contact with primary care providers to provide patient- and physician-level support, consultation, and episodes of care as necessary. Rates of anxiety, depression, and MCI diagnosis/detection, time to treatment initiation, and improvement in symptom burden will be assessed.

If patients born in 1950, 1952 and 1956 reach a threshold level of anxiety, depression, or MCI symptom burden, these individuals will form our comparison group and will receive treatment as usual (TAU).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
60 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • Diagnosis of dementia.
  • Substance abuse identified as an acute problem in the four weeks before being enrolled in the study (i.e. the day the patient signs the informed consent form).
  • Those with delirium, or where we are unable to make a diagnosis of MCI, due to unstable comorbidities.
  • Palliative-care patients.

研究组 & 干预措施

Enrolled Cases

Experimental

Integrated Care Pathway with different treatment interventions

Interventions include:

Sertraline, Venlafaxine, CBT/Psychological therapy, Psychiatric consultation, lifestyle intervention resources

干预措施: Lifestyle Intervention Resources (Other)

Enrolled Cases

Experimental

Integrated Care Pathway with different treatment interventions

Interventions include:

Sertraline, Venlafaxine, CBT/Psychological therapy, Psychiatric consultation, lifestyle intervention resources

干预措施: Sertraline (Drug)

Enrolled Cases

Experimental

Integrated Care Pathway with different treatment interventions

Interventions include:

Sertraline, Venlafaxine, CBT/Psychological therapy, Psychiatric consultation, lifestyle intervention resources

干预措施: Venlafaxine (Drug)

Enrolled Cases

Experimental

Integrated Care Pathway with different treatment interventions

Interventions include:

Sertraline, Venlafaxine, CBT/Psychological therapy, Psychiatric consultation, lifestyle intervention resources

干预措施: CBT/Psychological Therapy (Other)

Enrolled Cases

Experimental

Integrated Care Pathway with different treatment interventions

Interventions include:

Sertraline, Venlafaxine, CBT/Psychological therapy, Psychiatric consultation, lifestyle intervention resources

干预措施: Psychiatric Consultation (Other)

结局指标

主要结局

Change in anxiety/depression/quality of life (QOL) scores among participants in the ICP and comparison groups

时间窗: From Baseline Screening to 24 month follow-up

Comparison for the GAD-7/PHQ-9/QOL scores will be assessed using Group x Time ANOVAs repeated measure comparing scores at assessment times in the intervention and comparison groups.

次要结局

  • Acceptability and perceived utility of the ICP(Baseline to 24 month follow-up)
  • Feasibility of the ICP(Baseline to 24 month follow-up)
  • Time-to-treatment initiation among those in the ICP arm versus those in the comparison arm.(Baseline to 24 month followup)
  • Specific Aim 3a: To assess the impact of the ICP on the rates of diagnoses/detection among older patients with anxiety, depression, or MCI compared to before ICP implementation.(Calculate one year prior to the time of Site Initiation Visit for all recruiting sites.)
  • Specific Aim 3b: To assess the impact of ICP on rates of diagnoses/detection among patients of the same age cohort as our target ICP population, but not in our study sample.(Calculate the 6 month period prior to the last study assessment for a given recruitment site.)
  • Changes in the primary care providers' knowledge of, and ability to recognize and manage, depression, anxiety, and MCI in older adults.(Baseline to 24 month follow-up)
  • Adjustments made for the adoption of the ICP in primary care teams(Baseline to 24 month follow-up)
  • Barriers to implementation of the ICP and the key elements to initiate, sustain and spread the ICP(Baseline to 24 month follow-up)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Tarek Rajji

Dr.

Centre for Addiction and Mental Health

研究点 (1)

Loading locations...

相似试验